Evidence map›Paper›PMID 27301678›Full record

ArticleBioorganic & medicinal chemistry2016

Selective photodepletion of malignant T cells in extracorporeal photopheresis with selenorhodamine photosensitizers.

Zachariah A McIver, Mark W Kryman, Young Choi, Benjamin N Coe, Gregory A Schamerhorn, Michelle K Linder, Kellie S Davies, Jacqueline E Hill, Geri A Sawada, Jason M Grayson and 1 more

Abstract read
In one paragraph

Article in Bioorganic & medicinal chemistry, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 11 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Zachariah A McIverDepartment of Hematology and Oncology, Wake Forest University School of Medicine, Winston-Salem, NC 27157, United States. Electronic address: zmciver@wakehealth.edu.
Mark W KrymanDepartment of Chemistry, University at Buffalo, The State University of New York, Buffalo, NY 14260, United States. Electronic address: markkrym@buffalo.edu.
Young ChoiDepartment of Hematology and Oncology, Wake Forest University School of Medicine, Winston-Salem, NC 27157, United States. Electronic address: ychoi@wakehealth.edu.
Benjamin N CoeDepartment of Hematology and Oncology, Wake Forest University School of Medicine, Winston-Salem, NC 27157, United States. Electronic address: bncoe@wakehealth.edu.
Gregory A SchamerhornDepartment of Chemistry, University at Buffalo, The State University of New York, Buffalo, NY 14260, United States. Electronic address: gregorys@buffalo.edu.
Michelle K LinderDepartment of Chemistry, University at Buffalo, The State University of New York, Buffalo, NY 14260, United States. Electronic address: mklinder@buffalo.edu.
Kellie S DaviesDepartment of Chemistry, University at Buffalo, The State University of New York, Buffalo, NY 14260, United States. Electronic address: kdavies@buffalo.edu.
Jacqueline E HillDepartment of Chemistry, University at Buffalo, The State University of New York, Buffalo, NY 14260, United States. Electronic address: jehill@buffalo.edu.
Geri A SawadaDrug Disposition, Eli Lilly and Company, Indianapolis, IN 46285, United States. Electronic address: sawada_geri_a@lilly.com.
Jason M GraysonDepartment of Microbiology and Immunology, Wake Forest University School of Medicine, Winston-Salem, NC 27157, United States. Electronic address: grayson@wakehealth.edu.
Michael R DettyDepartment of Chemistry, University at Buffalo, The State University of New York, Buffalo, NY 14260, United States. Electronic address: mdetty@buffalo.edu.
University at Buffalo, State University of New York · USWake Forest University · USEli Lilly (United States) · US

Funding

Tumor Tissue CoreP30CA012197 · NCI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI Ruben A. Mesa · 1985 to 2026
$55.4M
Repurposed Drugs to Inhibit Human T Cells and AutoimmunityR03AI109224 · NIAID · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI GRAYSON, JASON MITCHELL · 2014 to 2015
$155k
NCI NIH HHS P30 CA012197NIAID NIH HHS R03 AI109224
6 · The paper itself

Abstract

Extracorporeal photopheresis (ECP) has been used successfully in the treatment of erythrodermic cutaneous T cell lymphoma (CTCL), and other T cell-mediated disorders. Not all patients obtain a significant or durable response from ECP. The design of a selective photosensitizer that spares desirable lymphocytes while targeting malignant T cells may promote cytotoxic T cell responses and improve outcomes after ECP. A series of selenorhodamines built with variations of the Texas red core targeted the mitochondria of malignant T cells, were phototoxic to malignant T cells presumably via their ability to generate singlet oxygen, and were transported by P-glycoprotein (P-gp). To determine the selectivity of the photosensitizers in the ECP milieu, staphylococcal enterotoxin B (SEB)-stimulated and non-stimulated human lymphocytes were combined with HUT-78 cells (a CTCL) to simulate ECP. The amide-containing analogues of the selenorhodamines were transported more rapidly than the thioamide analogues in monolayers of MDCKII-MDR1 cells and, consequently, were extruded more rapidly from P-gp-expressing T cells than the corresponding thioamide analogues. Selenorhodamine 6 with the Texas red core and a piperidylamide functionality was phototoxic to >90% of malignant T cells while sparing >60% of both stimulated and non-stimulated T cells. In the resting T cells, (63±7)% of the CD4+ T cell compartment, and (78±2.5)% of the CD8+ cytotoxic T cell population were preserved, resulting in an enrichment of healthy and cytotoxic T cells after photodepletion.

Indexed as

PhotopheresisATP Binding Cassette Transporter, Subfamily B, Member 1Cell Line, TumorHumansLightLymphomaMitochondriaOrganoselenium CompoundsPhotosensitizing AgentsRhodaminesT-LymphocytesVerapamilATP Binding Cassette Transporter, Subfamily B, Member 1Organoselenium CompoundsPhotosensitizing AgentsRhodaminesVerapamilP-glycoproteinPhotopheresisPhototherapySelenorhodaminesT cell malignancy

Identifiers

PMID27301678
PMCPMC5815522
OpenAlexW2418394635

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.